In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …

The drug treatment of Parkinson's disease (PD) is accompanied by a loss of drug efficacy,
the onset of motor complications, lack of effect on non-motor symptoms, and a failure to …

The development of non-dopaminergic therapies for Parkinson's disease (PD) has attracted
much interest in recent years. Among new classes of drugs, adenosine A2A antagonists …

Adenosine A 2A receptor antagonists represent a new way forward in the symptomatic
treatment of Parkinson's disease (PD) through a non-dopaminergic mechanism. As a class …

Adenosine derived from the degradation of ATP/AMP functions as a signalling molecule in
the nervous system through the occupation of A1, A2, and A3 adenosine receptors …

Adenosine A2A receptors present in the central nervous system have been implicated in the
modulation of motor functions. Accordingly, adenosine A2A receptor antagonists currently …

Improving the translation of novel findings from basic laboratory research to better therapies
for neurologic disease constitutes a major challenge for the neurosciences. This brief review …

The adenosine A 2A receptor has emerged as an attractive non-dopaminergic target in the
pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS …

Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine,
glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and …

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder,
affecting up to 10 million people worldwide. Current treatment primarily involves symptom …